2025-11-06 - Analysis Report
Okay, here's an analysis of Transmedics Group Inc. (TMDX) based on the provided information. I will present the data with concise numerical summaries, followed by brief analyses.

**Report: Transmedics Group Inc. (TMDX) Analysis**

**Company Overview:** Transmedics Group Inc. is a medical technology company pioneering a novel organ care system for transplantation therapy.

**1. Performance vs. S&P 500 (VOO)**

*   **TMDX Cumulative Return:** 215.90%
*   **VOO Cumulative Return:** 74.76%
*   **Absolute Deviation:** 158.6%
*   **Relative Deviation:** 72.5%

**Analysis:** TMDX has significantly outperformed the S&P 500. The relative deviation suggests that its outperformance is in the higher percentile compared to its historical performance versus the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD    | Alpha   | Beta   | Cap(B) |
|------------|----------|--------|---------|--------|--------|
| 2019-2021  | -18.0%   | 83.5%  | -61.0%  | -0.0   | 0.7    |
| 2020-2022  | 94.0%    | 83.5%  | 95.0%   | 0.0    | 2.1    |
| 2021-2023  | 65.0%    | 80.5%  | 64.0%   | 0.1    | 2.7    |
| 2022-2024  | 130.0%   | 85.5%  | 109.0%  | 0.1    | 2.1    |
| 2023-2025  | 137.0%   | 85.5%  | 73.0%   | 0.3    | 4.3    |

**Analysis:**

*   **CAGR:** Shows strong growth in recent periods (2020-2025).
*   **MDD:** High Maximum Drawdown values indicate significant volatility.
*   **Alpha:** Consistently positive Alpha indicates outperformance relative to its risk (Beta).
*   **Beta:** Low Beta values suggest low correlation with the market (S&P 500).  Beta is increasing over the most recent periods.

**2. Recent Price Action**

*   **Current Price:** 127.21
*   **Previous Close:** 122.21
*   **Change:** 4.09
*   **5-Day Moving Average:** 130.72
*   **20-Day Moving Average:** 122.12
*   **60-Day Moving Average:** 118.54

**Analysis:** The price increased significantly compared to the previous close, which suggests a strong upward price movement. The current price is below the 5-day moving average but above the 20-day and 60-day moving averages, suggesting a short-term pullback after a recent uptrend.

**3. Indicators and Signals**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 68.69
*   **PPO:** 0.33
*   **Hybrid Signal:** Buy 100% of cash (8 shares). Monthly invest 1.2% of total investment ($1,000.00)
*   **20-Day Relative Deviation Change:** +10.0 (Short-Term Increase)
*   **Expected Return:** 36.0%

**Analysis:**

*   **MRI:** A high MRI score suggests the stock is considered a relatively safe investment at this time.
*   **RSI:** An RSI of 68.69 indicates the stock is approaching overbought territory, but not yet at extreme levels.
*   **PPO:** The Positive PPO suggests the price trend is upward.
*   **Delta_Previous_Relative_Divergence:** Recent increase in relative deviation indicates short-term upward momentum.
*   **Expected Return:** A 36.0% expected return is optimistic and suggests the potential for significant outperformance versus the S&P 500 over a longer investment horizon.
*   The large change in price from the previous close indicates a noteworthy event driving the stock's movement.

**4. Recent News & Significant Events:**

*   **Valuation:** Multiple articles suggest the stock may be undervalued (Simply Wall St.).
*   **Earnings & Growth:** Articles highlight strong Q3 results, upgraded growth outlook, and increasing net profit margin (Zacks, Simply Wall St.).
*   **Inducement Grants:** A PR Newswire release reports inducement grants.

**Analysis:** Recent news is predominantly positive, focusing on undervaluation, strong financial performance, and positive growth outlook.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.67 (~Buy)
*   **Number of Opinions:** 11
*   **Target Price (Avg/High/Low):** 141.91 / 170.00 / 114.00

**Analysis:**  Analyst consensus is strongly positive with a "Buy" rating. The average target price suggests an upside potential from the current price.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-10-29 | 0.66 | 0.37         |
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |

**Analysis:**  TMDX has consistently beaten EPS estimates in recent quarters, demonstrating strong earnings performance.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | \$0.16B   | 61.38%        |
| 2025-03-31 | \$0.14B   | 61.47%        |
| 2024-12-31 | \$0.12B   | 59.21%        |
| 2024-09-30 | \$0.11B   | 55.94%        |
| 2024-06-30 | \$0.11B   | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | \$0.32B   | 10.97%  |
| 2025-03-31 | \$0.27B   | 9.64%   |
| 2024-12-31 | \$0.23B   | 3.00%   |
| 2024-09-30 | \$0.21B   | 2.01%   |
| 2024-06-30 | \$0.19B   | 6.42%   |

**Analysis:**

*   **Revenue:**  Consistently increasing revenue quarter-over-quarter indicates strong growth.
*   **Profit Margin:**  High and relatively stable profit margins suggest efficient operations.
*   **Equity:**  Increasing equity reflects the company's growth and retained earnings.
*   **ROE:**  Increasing ROE indicates improving profitability relative to equity.

**7. Overall Summary**

Transmedics Group Inc. (TMDX) demonstrates strong financial performance, high growth potential, and positive market sentiment. The company has significantly outperformed the S&P 500, boasts increasing revenue and profitability, and receives favorable analyst ratings. Recent news suggests the stock may be undervalued. While the stock exhibits high volatility (MDD), the Market Risk Indicator suggests relatively low risk and the recent earnings reports have exceeded expectations, indicating solid financial management. Given the positive Hybrid Signal, continued fundamental growth and analyst expectations of continued growth in the sector, this stock could be considered a good investment.
